Published: 2 December 2021


MARC’s remarks: September 2021 meeting

Published: 2 December 2021
Prescriber Update 42(4): 50
December 2021

The Medicines Adverse Reactions Committee (MARC) convened via videoconference on 9 September 2021.

The benefits and risks of phentermine were discussed. The Committee noted that although the evidence regarding safety and efficacy is limited, phentermine has a role in bariatric medicine. The Committee considered that the benefits of treatment with phentermine outweigh the risks of harm and no further action is needed.

The risk of fetal renal impairment and oligohydramnios with the use of non-steroidal anti-inflammatory drugs (NSAIDs) during the second trimester of pregnancy was discussed. The Committee recommended that the pregnancy information should be aligned across all NSAID data sheets and should include a warning about the risk of oligohydramnios in the second trimester. A harmonised statement will be agreed on at a future meeting. The Committee also recommended that the safety of NSAIDs in the third trimester of pregnancy should be discussed at this future meeting as this information is not consistent across NSAID data sheets.

See the Medsafe website for the MARC meeting minutes and the reports presented to the MARC.

Hide menus
Show menus
0 1 2 4 5 6 7 9 [ /